Your session is about to expire
← Back to Search
Procedure
Deep Brain Stimulation for Post-Traumatic Stress Disorder
Phase 1
Recruiting
Led By Nir Lipsman, MD PhD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of posttraumatic stress disorder as defined by the Diagnostic and Statistical Manual fifth edition (DSM-5)
Female or Male patients between age 18-70
Must not have
Active neurologic disease, such as epilepsy
Current suicidal ideation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 2 weeks until the 8 weeks mark, every 4 weeks until 6 month mark and every two months until the 2 year mark
Summary
This trial aims to explore a surgical treatment for treatment refractory PTSD, a severe mental health condition that currently has limited effective treatment options. The study will involve three stages: pre-operative, operative, and
Who is the study for?
This trial is for individuals with severe PTSD that hasn't improved after trying other treatments. Participants must be eligible for surgery, willing to undergo various pre-operative tests like MRI and CT scans, and commit to regular follow-up visits post-surgery.
What is being tested?
The study is testing Deep Brain Stimulation (DBS) as a surgical treatment for refractory PTSD by targeting the subgenual cingulate. It includes three stages: pre-operative assessments, the surgical procedure of implanting electrodes and an internal pulse generator, followed by biweekly then monthly programming visits.
What are the potential side effects?
Potential side effects may include discomfort or complications from wearing a stereotactic frame during surgery, risks associated with general anesthesia, infection risk at incision sites, possible bleeding or brain injury during electrode insertion.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with PTSD according to the DSM-5.
Select...
I am between 18 and 70 years old.
Select...
My PTSD is severe, with a CAPS score of 50 or higher.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have an active neurological condition like epilepsy.
Select...
I am currently experiencing thoughts of harming myself.
Select...
I have health issues that could make surgery risky.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 2 weeks until the 8 weeks mark, every 4 weeks until 6 month mark and every two months until the 2 year mark
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 2 weeks until the 8 weeks mark, every 4 weeks until 6 month mark and every two months until the 2 year mark
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinician-Administered PTSD Scale for DSM-5 (CAPS)
Number of participants with treatment-related adverse events as assessed by SAFTEE
Secondary study objectives
Hamilton Depression Rating Scale (HAMD)
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Prolonged exposure therapyExperimental Treatment1 Intervention
Prolonged exposure therapy (from postoperative week 34to 44)
Group II: Open labelExperimental Treatment1 Intervention
1) Open label phase (from surgery until postoperative week 24)
Group III: Closed-loop DBSExperimental Treatment1 Intervention
Closed-loop DBS (from postoperative week 45 to 60).
Group IV: Double-blinded "on/off" phasePlacebo Group1 Intervention
Double-blinded "on/off" phase (from postoperative week 25 to 33)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prolonged exposure therapy
2009
N/A
~220
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
681 Previous Clinical Trials
1,565,738 Total Patients Enrolled
Nir Lipsman, MD PhDPrincipal InvestigatorSunnybrook Health Sciences Centre
1 Previous Clinical Trials
23 Total Patients Enrolled